Replimune Group (NASDAQ:REPL) Upgraded at Wedbush

Key Points

• Replimune Group received an upgrade from Wedbush from a "neutral" to an "outperform" rating, with a new target price of $18.00, suggesting a potential upside of 300% from its current stock price.
• Despite the positive outlook from some analysts, several firms like Leerink Partners and Barclays have reduced their target prices significantly, with Barclays setting a new target at $3.00.
• The company reported a quarterly earnings miss, posting a loss of ($0.95) per share against analyst expectations of ($0.83).

Replimune Group (NASDAQ:REPL - Get Free Report) was upgraded by equities research analysts at Wedbush from a "neutral" rating to an "outperform" rating in a research note issued on Monday, MarketBeat Ratings reports. The brokerage presently has a $18.00 target price on the stock. Wedbush's price objective would indicate a potential upside of 300.00% from the company's current price.

Several other analysts also recently commented on REPL. Cantor Fitzgerald raised shares of Replimune Group from a "neutral" rating to an "overweight" rating in a research report on Wednesday, July 30th. Leerink Partners reiterated a "market perform" rating and set a $3.00 price target (down previously from $21.00) on shares of Replimune Group in a report on Tuesday, July 22nd. Piper Sandler lowered shares of Replimune Group from an "overweight" rating to a "neutral" rating and set a $3.00 price objective for the company. in a report on Tuesday, July 22nd. Barclays cut Replimune Group from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $17.00 to $3.00 in a research report on Wednesday, July 23rd. Finally, BMO Capital Markets lowered Replimune Group from an "outperform" rating to an "underperform" rating and reduced their target price for the stock from $27.00 to $2.00 in a report on Wednesday, July 23rd. Three research analysts have rated the stock with a Buy rating, five have issued a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat, Replimune Group has an average rating of "Hold" and an average target price of $8.25.

Replimune Group Price Performance

REPL stock opened at $4.50 on Monday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.94 and a current ratio of 6.94. The firm has a 50 day moving average price of $5.03 and a 200-day moving average price of $7.27. Replimune Group has a 52-week low of $2.68 and a 52-week high of $17.00. The firm has a market capitalization of $351.27 million, a price-to-earnings ratio of -1.39 and a beta of 0.42.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). Equities research analysts forecast that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Emily Luisa Hill sold 9,154 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $5.37, for a total value of $49,156.98. Following the transaction, the chief financial officer directly owned 134,368 shares in the company, valued at $721,556.16. The trade was a 6.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 5.20% of the company's stock.

Institutional Investors Weigh In On Replimune Group

Several large investors have recently added to or reduced their stakes in REPL. Vanguard Group Inc. boosted its position in Replimune Group by 6.6% in the 1st quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company's stock valued at $37,372,000 after buying an additional 237,185 shares during the period. Millennium Management LLC boosted its stake in Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company's stock worth $11,927,000 after purchasing an additional 33,574 shares in the last quarter. MPM Bioimpact LLC lifted its position in Replimune Group by 3.9% during the 1st quarter. MPM Bioimpact LLC now owns 987,036 shares of the company's stock worth $9,624,000 after acquiring an additional 37,036 shares during the period. Parkman Healthcare Partners LLC boosted its position in Replimune Group by 9.3% in the first quarter. Parkman Healthcare Partners LLC now owns 950,399 shares of the company's stock valued at $9,266,000 after buying an additional 80,640 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock worth $6,729,000 after acquiring an additional 119,145 shares during the period. 92.53% of the stock is owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.